Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 1 of 1 (100%) have an AI response strategy ready
Beijing Sinotau Bio-Pharmaceuticals Technology Co. Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner and 1 art unit, keeping prosecution within one examination framework.
PATTERSON, SARAH COOPER is the busiest examiner and handles the pending matter. Counsel can focus on the examiner’s treatment of the claims and the relevant art-unit practice.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PATTERSON, SARAH COOPER | 1 | 55.8% | +53.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17909658 | COMBINED USE OF CTB006 AND PONATINIB | PATTERSON, SARAH COOPER | 28d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17909658 | COMBINED USE OF CTB006 AND PONATINIB | PATTERSON, SARAH COOPER | 28d |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17909658 | COMBINED USE OF CTB006 AND PONATINIB | PATTERSON, SARAH COOPER | 1675 | §102§103§112Other | Final Rejection | 28d | AI Ready | Sep 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeijing Sinotau Bio-Pharmaceuticals Technology Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Sarah Cooper Patterson has the most, with 1 of Beijing Sinotau Bio-Pharmaceuticals Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.